Serina Therapeutics raises $5M via convertible preferred stock for Parkinson's drug SER-252

Serina Therapeutics, Inc.

Issued 962,250 shares of Series A Convertible Preferred at $5.18/share for ~$5M gross proceeds.
Preferred stock carries 8% cumulative annual dividend, paid in kind; convertible at $5.18 per common share.
Proceeds to support SER-252 (POZ-apomorphine) Phase 1 trial initiation in Q4 2025 for advanced Parkinson's.
Financing from strategic shareholders; conversion triggers include stock price doubling or $20M+ equity raise.

item 1.01 item 3.02 item 3.03 item 5.03 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Serina Therapeutics, Inc.: Filed Certificate of Designations for Series A Convertible Preferred Stock, establishing rights, preferences, and limitations (effective 2025-04-10).

Change: charter amendment
Effective: 2025-04-10

Exact text from the filing

On April 10, 2025, the Company filed a Certificate of Designations of Preferences, Rights and Limitations of Series A Convertible Preferred Stock (the "Certificate of Designations") with the Secretary of State of the State of Delaware, which became effective upon filing.

View on SEC.gov

77 governance changes filed in the last 30 days. Browse all governance changes →

Serina Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001708599-25-000042

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.